Topotarget, results keep rolling in

By On 14. June 2012 · Leave a Comment · In Topotarget

Practically every day these weeks, new surveys and studies are being published about Belinostat. Today,  a study regarding the effect of belinostat in International Journal of Gynecological Cancer titled:

Phase II Activity of Belinostat (PXD-101), Carboplatin, and Paclitaxel in Women With Previously Treated Ovarian Cancer

Conclusions: Belinostat, carboplatin, and paclitaxel combined was reasonably well tolerated and demonstrated clinical benefit in heavily-pretreated patients with EOC. The addition of belinostat to this platinum-based regimen represents a novel approach to EOC therapy and warrants further exploration.

About Stengaard

BioPorto investor from way back when... I've invested in BioPorto ever since they made their debut on the danish stock exchange, it been a looooong journey with many obstacles. But well worth it all if Bioporto maintains their patent after the proceedings in 2014, and enters into agreements with Global Distributors in 2012 and 2013 If not, then it'll take another xx.years 🙂

Related posts:

  1. TopoTarget ‘s Belinostat effective in pancreatic cancer Last week saw the publication of a paper on TopoTarget...
Tagged with: • •
 

Leave a Reply

Your email address will not be published. Required fields are marked *

Set your Twitter account name in your settings to use the TwitterBar Section.